Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...

Polyrizon Ltd., a biotech company focused on developing intranasal hydrogels, has started preclinical studies for an intranasal formulation of Naloxone, intended to treat opioid overdoses.

Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...

There was no difference in survival between recipients of 4-mg or 8-mg intranasal naloxone (Narcan) administered by law enforcement, according to data from New York state. A review of 354 naloxone ...

Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversal in Real-World Emergencies Ra’anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ...

A higher dose version of naloxone, the nasal spray used to reverse opioid-induced overdoses, did not lead to more saved lives, according to a new study published earlier this month. The findings, ...

Ra’anana, Israel, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today ...

Though many Illinois libraries already have supplies of medications that can reverse opioid overdoses, a new state law will ...

RA’ANANA, ISRAEL - Polyrizon Ltd. (NASDAQ:PLRZ) announced Thursday that its intranasal naloxone hydrogel formulation demonstrated favorable permeation kinetics in preclinical testing, complementing ...

The University of Michigan Health-Sparrow has installed Narcan vending machines at its Carson and Clinton community hospitals ...